Trial
NCT04272775
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Relapsed and/or Refractory Multiple Myeloma
Intervention
Ixazomib
Why stopped
Business Decision; No Safety Or Efficacy Concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-17